Experimental Hematology
Volume 34, Issue 10 , Pages 1377-1384 , October 2006

Cytotoxic and biochemical effects of 3,3′,4,4′,5,5′-hexahydroxystilbene, a novel resveratrol analog in HL-60 human promyelocytic leukemia cells

  • Zsuzsanna Horvath

      Affiliations

    • Clinical Institute of Medical and Chemical Laboratory Diagnostics, General Hospital of Vienna, Medical University of Vienna, Vienna, Austria
    • ,
  • Marek Murias

      Affiliations

    • Department of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna, Vienna, Austria
    • ,
  • Philipp Saiko

      Affiliations

    • Clinical Institute of Medical and Chemical Laboratory Diagnostics, General Hospital of Vienna, Medical University of Vienna, Vienna, Austria
    • ,
  • Thomas Erker

      Affiliations

    • Department of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna, Vienna, Austria
    • ,
  • Norbert Handler

      Affiliations

    • Department of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna, Vienna, Austria
    • ,
  • Sibylle Madlener

      Affiliations

    • Institute of Clinical Pathology, Medical University of Vienna, Vienna, Austria
    • ,
  • Walter Jaeger

      Affiliations

    • Department of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna, Vienna, Austria
    • ,
  • Michael Grusch

      Affiliations

    • Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, Vienna, Austria
    • ,
  • Monika Fritzer-Szekeres

      Affiliations

    • Clinical Institute of Medical and Chemical Laboratory Diagnostics, General Hospital of Vienna, Medical University of Vienna, Vienna, Austria
    • ,
  • Georg Krupitza

      Affiliations

    • Institute of Clinical Pathology, Medical University of Vienna, Vienna, Austria
    • ,
  • Thomas Szekeres

      Affiliations

    • Clinical Institute of Medical and Chemical Laboratory Diagnostics, General Hospital of Vienna, Medical University of Vienna, Vienna, Austria
    • Corresponding Author InformationOffprint requests to: Thomas Szekeres, M.D., Ph.D., Clinical Institute of Medical and Chemical Laboratory Diagnostics, General Hospital of Vienna, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria

Received 8 December 2005 ,Revised 30 March 2006 ,Accepted 30 May 2006.

References 

  1. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet. 1992;339:1523–1526
  2. Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997;275:218–220
  3. Banerjee S, Buenos-Ramos C, Aggarwal BB. Supression of 7,12 dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor kappa B, cyclooxygenase 2, and matrix metalloproteinase 9. Cancer Res. 2002;62:4945–4954
  4. Pozo-Guisado E, Alvarez-Barrientos A, Mulero-Navarro S, Santiago-Josefat B, Fernandez-Salguero PM. The antiproliferative activity of resveratrol results in apoptosis in MCF-7 but not in MDA-MB-231 human breast cancer cells: cell-specific alteration of the cell cycle. Biochem Pharmacol. 2002;64:1375–1386
  5. Zhou HB, Yan Y, Sun YN, Zhu JR. Resveratrol induces apoptosis in human esophageal carcinoma cells. World J Gastroenterol. 2003;9:408–411
  6. Ferry-Dumazet H, Gernier O, Mamani-Matsuda M, et al. Resveratrol inhibits the growth and induces the apoptosis of both normal and leukemic hematopoietic cells Carcinogenesis. 2002;23:1327–1333.
  7. Mouria M, Gukovskaya AS, Jung Y, et al. Food-derived polyphenols inhibit pancreatic cancer growth through mitochondrial cytochrome C release and apoptosis. Int J Cancer. 2002;98:761–769
  8. Clement MV, Hirpara JL, Chawdhury SH, Perviaz S. Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD 95 signaling-dependent apoptosis in human tumor cells. Blood. 1998;92:996–1002
  9. Dorrie J, Gerauer H, Wachter Y, Zunino SJ. Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Cancer Res. 2001;61:4731–4739
  10. Fontecave M, Lepoivre M, Elleingand E, Gerez C, Guittet O. Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett. 1998;421:277–279
  11. Elford HL, Freese M, Passamani E, Morris HP. Ribonucleotide reductase and cell proliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas. J Biol Chem. 1970;245:5228–5233
  12. Stivala LA, Savio M, Carafoli F, et al. Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol. J Biol Chem. 2001;276:22586–22594
  13. Hsieh TC, Juan G, Darzynkiewicz Z, Wu JM. Resveratrol increases nitric oxide synthase, induces accumulation of p53 and p21 (WAF1/CIP1), and suppresses cultured bovine pulmonary artery endothelial cell proliferation by perturbing progression through S and G2. Cancer Res. 1999;59:2596–2601
  14. Estrov Z, Shishodia S, Faderl S, et al. Resveratrol blocks interleukin-1 beta–induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apotposis of acute myeloid leukemia cells. Blood. 2003;102:987–995
  15. Ragione FD, Cucciolla V, Borriello A, et al. Resveratrol arrests the cell division cycle at S/G2 phase transition. Biochem Biophys Res Commun. 1998;250:53–58
  16. Bernhard D, Tinhofer I, Tonko M, et al. Resveratrol causes arrest in the S-phase prior to Fas-independent apoptosis in CEM-C7H2 acute leukemia cells. Cell Death Differ. 2000;7:834–842
  17. Potter GA, Patterson LH, Wanogho E, et al. The cancer chemopreventive agent resveratrol is converted to the anti-cancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br J Cancer. 2002;86:774–778
  18. Wieder T, Prokop A, Bagci B, et al. Piceatannol, a hydroxylated analogue of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary, leukemic lymphoblasts. Leukemia. 2001;15(11):1735–1742
  19. Wolter F, Clausnitzer A, Akoglu B, Stein J. Piceatannol, a natural analog of resveratrol, inhibits progression through the S phase of cell cycle in colorectal cancer cell lines. J Nutr. 2002;132:298–302
  20. Larrosa M, Tomas-Barberan FA, Espin JC. The grape and wine polyphenol piceatannol is a potent inducer of apoptosis in human SK-Mel-28 melanoma cells. Eur J Nutr. 2004;43:275–284
  21. Ferrigni NR, McLaughlin JL, Powell RG, Smith CR. Use of potato disc and brine shrimp bioassays to detect activity and isolate piceatannol as the antileukemic principle from the seeds of Euphorbia lagascae. J Nat Prod. 1984;47:347–352
  22. Larrosa M, Tomas-Barberan FA, Espin JC. Grape polyphenol resveratrol and the related molecule 4-hydroxystilbene induce growth inhibition, apoptosis, S-phase arrest, and upregulation of cyclins A, E, and B1 in human SK-Mel-28 melanoma cells. J Agric Food Chem. 2003;51:4576–4584
  23. Holmes-McNary M, Baldwin AS. Chemopreventive properties of trans resveratrol are associated with inhibition of activation of the IκB kinase. Cancer Res. 2000;60:3477–3483
  24. Ashikawa K, Majumdar S, Banerjee S, Bharti AC, Shishodia S, Aggarwal BB. Piceatannol inhibits TNF-induced NF-κB activation and NF-κB mediated gene expression through suppression of IκBα kinase and p65 phosphorylation. J Immunol. 2002;169:6490–6497
  25. Kuwano T, Nakao S, Yamamoto H, et al. Cyclooxygenase 2 is a key enzyme for inflammatory cytokine–induced angiogenesis. FASEB J. 2004;4:289–298
  26. Marrogi AJ, Travis WD, Welsh JA, et al. Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non–small cell lung carcinoma. Clin Cancer Res. 2000;6:4739–4744
  27. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer. 2001;1:11–21
  28. Garcia Rodriguez LA, Gonzalez-Perez A. Risk of breast cancer among users of aspirin and other anti-inflammatory drugs. Br J Cancer. 2004;91:525–529
  29. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM. Cyclooxygenases in cancer: progress and perspective. Cancer Lett. 2004;215:1–20
  30. Murias M, Handler N, Erker T, et al. Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship. Bioorg Med Chem. 2004;12:5571–5578
  31. Murias M, Jager W, Handler N, et al. Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure-activity relationship. Biochem Pharmacol. 2005;69:903–912
  32. Horvath Z, Saiko P, Illmer C, et al. Synergistic action of resveratrol, a ingredient of wine, with Ara-C and tiazofurin in HL-60 human promyelocytic leukemia cells. Exp Hematol. 2005;33:329–335
  33. Garrett C, Santi DV. A rapid and sensitive high pressure liquid chromatography assay for deoxyribonucleoside triphosphates in cell extracts. Anal Biochem. 1979;99:268–273
  34. Davis JN, Sarkar FS. Soy Isoflavone supplementation in healthy men prevents NF-κB activation by TNF-α in blood lymphocytes. Free Rad Bio Med. 2001;11:1293–1302
  35. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55
  36. Gasparini G, Longo R, Sarmiento R, Morabito A. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?. Lancet Oncol. 2003;4:605–615
  37. Sinicrope FA, Gill S. Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev. 2004;23:63–75
  38. Harris RE, Chlebowski RT, Jackson RD, et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res. 2003;63:6096–6101
  39. Thun MJ, Namboodiri MM, Heath CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991;325:1593–1596
  40. Williams CS, Mann M, DuBois RN. The role of cycloxygenases in inflammation, cancer, and development. Oncogene. 1999;18:7908–7916
  41. Robinson BW, Im MM, Ljungman M, Praz F, Shewach DS. Enhanced radiosensitization with gemcitabine in mismatch repair-deficient HCT116 cells. Cancer Res. 2003 Oct 15;63:6935–6941
  42. Gandhi V, Estey E, Plunkett W. Modulation of arabinosylcytosine metabolism during leukemia therapy. Adv Exp Med Biol. 1994;370:119–124

PII: S0301-472X(06)00335-3

doi: 10.1016/j.exphem.2006.05.018

Experimental Hematology
Volume 34, Issue 10 , Pages 1377-1384 , October 2006

Article Tools

* Image Usage & Resolution